The novel role of epigenetics in primary prevention of cardiovascular diseases

I'm sure your doctor can tell you exactly how to prevent CV events.
http://scholar.google.com/scholar_url?hl=en&q=http://pagepressjournals.org/index.php/cardiogen/article/view/cardiogenetics.2012.e12/pdf&sa=X&scisig=AAGBfm2cd5v34ELJYFuTqQKH1JMGOAQQzA&oi=scholaralrt
Abstract
A great deal of evidences indicate that
impaired fetal growth and in utero exposure to
risk factors, especially maternal hypercholesterolemia,
may be relevant for human pathophysiological
signs of atherosclerosis and subsequent
development of cardiovascular disease
(CVD) during different life stages. Despite the
underlying mechanisms of fetal programming
are still unknown, epigenetics has been suggested
as one of the possible explanations for
the associations between intrauterine risk factors
and CVD development. Indeed, a lot of
translational studies support the hypothesis
that epigenetic changes are related to
increased CVD risk although it is still not possible
to establish a direct causality in humans.
Notably, epigenetic modifications can be
reversible through therapeutic approaches
employing histone deacetylase inhibitors, histone
acetyltransferase inhibitors and commonly
used drugs like statins. Thus, the whole
comprehension of these mechanisms will provide
in the next future the rationale for the
development of novel tools to be used in the
primary prevention and therapy of CVD.